Weight Loss News

Indian Pharmacies- Resolute To Not Haul Rimonabant from Market

20 June 2007

Indian pharmaceutical companies which recently introduced own generic equivalents of the diet drug rimonabant aver that the drug is safe and thus have not planned to extract the preparation from sell despite being acquainted with the fact that the safety of acomplia has been overwhelmingly questioned by the FDA's advisory last week.

Yet Indian regulatory authorities, as those which functions in Europe wherein the diet drug is been marketed for over a year, are now likely to reevaluate the condition contemplating the last week's undisputed suggestions provided by an FDA advisory panel in opposition to the acomplia approval to be sold in the U. S.

European regulators are anticipated to discuss the astonishing U.S. advances in a meet this week, but Indian regulators are geared up to have another look on the data in addition.

"In our pharmaco-vigilance programme, we will make efforts to analyze all overseas developments and their consequent repercussions on Indian buyers," asserted Dr. Venkateswarlu, Drugs Controller General of India.

Pharmaceuticals marketing rimonabant into the Indian market have found succor in the fact that there have been cases in the past wherein Indian regulators permitted pharmaceutical companies to sell those drugs which enjoyed acceptance in Europe but not in the U. S.

Torrent Pharmaceutical Vice President Ruchir Modi said: "The medicine is safe. We already carried out our own clinical trials in more than 100 patients and the consequent outcomes also have been promising. Yet, we will stick to the drugs controller general of India's regulations."

"Rimonabant has been approved in a number of European countries and no nation has inhibited it so far," added a spokesperson for Sun Pharma, another company engrossed in the sale of rimonabant's generic version.